Virax Biolabs Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025

Reuters

08/26

<a href="https://laohu8.com/S/VRAX">Virax Biolabs</a> Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025

Virax Biolabs Group Ltd., a biotechnology company specializing in immune response detection and diagnostics, has announced a partnership with Emory University's Center for the Advancement of Diagnostics for a Just Society to conduct clinical studies of their proprietary T cell testing technology, ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, specifically targeting post-acute sequelae of SARS-CoV-2, also known as long COVID. The collaboration is set to generate clinical data to support Virax's planned regulatory submissions and potential commercial rollout. The results of these studies have not yet been presented. Additionally, this partnership aligns with Virax's preparations for a pre-submission meeting with the U.S. Food and Drug Administration in early September 2025 to discuss the regulatory pathway for ViraxImmune™.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA58084) on August 26, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562073874"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562073874\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562073874?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562073874","market":"us","top_or_hot":-1,"title":"Virax Biolabs Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VRAX\">Virax Biolabs</a> Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Virax Biolabs Group Ltd., a biotechnology company specializing in immune response detection and diagnostics, has announced a partnership with Emory University's Center for the Advancement of Diagnostics for a Just Society to conduct clinical studies of their proprietary T cell testing technology, ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, specifically targeting post-acute sequelae of SARS-CoV-2, also known as long COVID. The collaboration is set to generate clinical data to support Virax's planned regulatory submissions and potential commercial rollout. The results of these studies have not yet been presented. Additionally, this partnership aligns with Virax's preparations for a pre-submission meeting with the U.S. Food and Drug Administration in early September 2025 to discuss the regulatory pathway for ViraxImmune™.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA58084) on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Virax Biolabs Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVirax Biolabs Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-26 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VRAX\">Virax Biolabs</a> Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Virax Biolabs Group Ltd., a biotechnology company specializing in immune response detection and diagnostics, has announced a partnership with Emory University's Center for the Advancement of Diagnostics for a Just Society to conduct clinical studies of their proprietary T cell testing technology, ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, specifically targeting post-acute sequelae of SARS-CoV-2, also known as long COVID. The collaboration is set to generate clinical data to support Virax's planned regulatory submissions and potential commercial rollout. The results of these studies have not yet been presented. Additionally, this partnership aligns with Virax's preparations for a pre-submission meeting with the U.S. Food and Drug Administration in early September 2025 to discuss the regulatory pathway for ViraxImmune™.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA58084) on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4175","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL3kB72s:1","article_id":"2562073874","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562073874","pubTimestamp":1756207836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Virax Biolabs Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune; Prepares for FDA Pre-Submission Meeting in September 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire  on August 26, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4175":"保健护理产品经销商","BK4583":"猴痘概念","VRAX":"Virax Biolabs Group Limited"},"translate_title":"Virax Biolabs Group Ltd.与埃默里大学合作开展ViraxImmune的临床研究；™为2025年9月FDA预提交会议做准备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRAX":0.9},"content_text":"Virax Biolabs Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025\n    \n\n        Virax Biolabs Group Ltd., a biotechnology company specializing in immune response detection and diagnostics, has announced a partnership with Emory University's Center for the Advancement of Diagnostics for a Just Society to conduct clinical studies of their proprietary T cell testing technology, ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, specifically targeting post-acute sequelae of SARS-CoV-2, also known as long COVID. The collaboration is set to generate clinical data to support Virax's planned regulatory submissions and potential commercial rollout. The results of these studies have not yet been presented. Additionally, this partnership aligns with Virax's preparations for a pre-submission meeting with the U.S. Food and Drug Administration in early September 2025 to discuss the regulatory pathway for ViraxImmune™.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA58084) on August 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}